Daily pill doubles survival in advanced pancreatic cancer, trial finds
A phase 3 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago shows that a daily oral drug, daraxonrasib, roughly doubled median survival for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The randomized study enrolled about 500 patients whose cancer had already spread; those taking daraxonrasib survived a median 13.2 … Read more